

Multimodalna analgezija

Doc. Dr Nenad Zornić
Služba za anesteziju i reanimaciju KC Kragujevac



Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Bol - definicija

- Bol predstavlja individualno, subjektivno iskustvo povezano sa aktuelnim ili potencijalnim oštećenjem tkiva, čija je manifestacija rezultat složene interreakcije fizioloških i neurohemiskih efekata sa psihosocijalnim faktorima.

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Akutni bol

- Akutni bol - bol u prvih 7 dana od operacije
- Hronični bol – bol koji traje duže od 3 meseca
- Akutni postoperativni bol – bol usled hirurške intervencije, kao i proceduralni bol (drenovi, sonde, kateteri).

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Patofiziologija postoperativnog bola

- bolna senzacija sa mesta hirurške incizije se razlikuje od drugih bolnih senzacija
 - (neuropatski bol, bol kao posledica inflamacije)
- hiperalgezija na mestu hirurške incizije: posredovana A δ i C vlaknima
- α -amino-3-hydroxy-5-methyl-4-isoxazole-propionate
- (AMPA)/kainate
- \downarrow pH \uparrow [laktata] – ishemijski mehanizam može da utiče na nastanak bola

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

Prediktori postoperativnog bola

- Preoperativni bol
- Mlađe životno doba
- Anksioznost
- Gojaznost
- Strah od intervencije
- Tip operacije (abdominalne, torakalne, ortopedske, dugog trajanja)

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Posebne subpopulacije bolesnika kod kojih bol može biti neadekvatno tretiran:

- pedijatrijski bolesnici
- gerijatrijski bolesnici
- kritično oboleli
- bolesnici sa oštećenim kognitivnim funkcijama

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Akutni bol

- Akutni bol nije samo neprijatno iskustvo
- Bol pokreće stresni odgovor na hiruršku traumu:
-
- Povećanje simpatičke aktivnosti
- Oslobođanje stres hormona
- Oštećenje imune funkcije
- Povećanje koagulabilnosti

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Akutni bol

- Povećanje simpatičke aktivnosti:
 - Tahikardija
 - Hipertenzija - povećana potrošnja kiseonika -- IM
 - ↑ SVR - smanjuje regionalni krvni protok u koži i potkoži – remeti zarastanje rana i pogoduje razvoju infekcije na mestu hirurškog rada
- Imobilizacija zbog bola + hiperkoagulabilnost:
 - venski tromboembolizam
 - plućna embolija

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

Akutni bol

Bol (abdomen, grudni koš) remeti:

Duboko disanje

Kašalj

Iskašljavanje



Atelektaza, hipoksemija, pneumonija

Bol pojačava katabolizam:

Stimuliše razgradnju proteina

Podiže nivo glikemije



Remeti zarastanje operativne rane

Psihološke posledice:

Remećenje sna

Psihomotorna agitacija

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

Akutni postoperativni bol

- tretman izuzetno značajan u postoperativnom lečenju bolesnika
- samo 1 od 4 hirurška bolesnika dobija adekvatnu postoperativnu analgetsku terapiju
- Holandija, 1420 bolesnika i pored protokola za postop. Terapiju bola 41% bolesnika imalo na dan operacije epizodu srednjeg do jakog bola
- USA, 250 bolesnika – 80% srednji do jak bol na dan operacije
 - 86% jak bol po otpustu iz bolnice
- Deca – nakon tonsilektomije i adenoidektomije: 86% značajan bol na dan I dan nakon operacije

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

Gde je problem ?

- Nejasno
- Multifaktorijelni problem
- Bol se tretira samo na zahtev
- Slaba komunikacija sa bolesnikom
- Ne procenjuje se intenzitet bola
- Ne pridržavanje protokola
- Ne korišćenje regionalnih tehnika analgezije (epidural, nervni blokovi...)

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Procena intenziteta bola

- **Ne proporučuje** se korišćenje vitalnih znakova (\uparrow Fr, \uparrow TA) kao **samostalnih** pokazatelja pristutva bola, već samo kao znak-upozorenje da treba bol proceniti primenom neke od navedenih skala.
- **Skale:** Behavioral pain scale (BPS) i Critical-Care Pain Observation Tool (CCPOT) su najverodostojnije i najpouzdanije skale za procenu bola kod ne-verbalnih bolesnika, odnosno numerička skala za verbalne bolesnike.

BEHAVIORAL PAIN SCALE (BPS)

Parametar	Bodovi (1-4)
Ekspresija lica	Relaksiran – 1 Delimično stegnut (nabrano čelo) – 2 Izrazito namršten (žmuri) -3 Grimase - 4
Pokreti gornjih ekstremiteta	Bez pokreta – 1 Delimično savijen -2 Kompl. savijen sa fleksijom prstiju – 3 Permanentna retrakcija - 4
Usklađenost sa mehaničkim ventilatorom	Toleriše – 1 Kašlje, ali uglavnom toleriše vent. – 2 Bori se sa ventilatorom -3 Ne može se kontrolisati ventilacija -4
Zbir: 3 – nema bola 12- maksimalni bol	

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"


Critical-Care Pain Observation Tool (CCPOT)

Indikator	Bodovi (0, 1, 2)
Ekspresija lica	Relaksiran – 0 Napet -1 Grimase -2
Pokreti tela	Bez pokreta – 0 Protektivni pokreti (dodiruje bolno mesto) -1 Nemiran, čupa tubus -2
Mišićna tenzija	Relaksiran – 0 Otpor na pasivne pokrete -1 Izrazita rezistencija na pokret -2
Usklađenost sa ventilatorom / vokalizacija	Toleriše (alarmi se ne uključuju) -0 Kašlje, ali toleriše -1 Bori se sa ventilatorom -2 Govori normalno -0 Uzdiše, stenje -1 Viče, jeca -2
Zbir 0 - 8	

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Procena intenziteta bola



Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Procena intenziteta bola

Choice of assessment tool




Fig A. Wong-Baker Faces Pain Rating Scale¹




Fig B. VRS²



Fig C. NRS²





Fig D. VAS²



¹ With permission from Elsevier.

² Adapted from McCaffery M, Pasero C. Pain: Clinical Manual 1999 with permission from Elsevier.

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

SPECIAL ARTICLES

Practice Guidelines for Acute Pain Management in the Perioperative Setting

An Updated Report by the American Society of Anesthesiologists Task Force on Acute Pain Management

PRACTICE Guidelines are systematically developed recommendations that assist the practitioner and patient in making decisions about health care. These recommendations may be adopted, modified, or rejected according to clinical needs and constraints and are not intended to replace local institutional policies. In addition, Practice Guidelines developed by the American Society of Anesthesiologists (ASA) are not intended as standards or absolute requirements, and their use cannot guarantee any specific outcome. Practice Guidelines are subject to revision as warranted by the evolution of medical knowledge, technology, and practice. They provide basic recommendations that are supported by a synthesis and analysis of

Updated by the American Society of Anesthesiologists (ASA) Committee on Standards and Practice Parameters, Jeffrey L. Apfelbaum, M.D., (Committee Chair), Chicago, Illinois; Michael A. Ashburn, M.D., M.P.H. (Task Force Chair), Philadelphia, Pennsylvania; Richard T. Connis, Ph.D., Woodinville, Washington; Tong J. Gan, M.D., Durham, North Carolina; and David G. Nickinovich, Ph.D., Bellevue, Washington. The previous update was developed by the ASA Task Force on Acute Pain Management: Michael A. Ashburn, M.D., M.P.H. (Chair), Salt Lake City, Utah; Robert A. Caplan, M.D., Seattle, Washington; Daniel B. Carr, M.D., Boston, Massachusetts; Richard T. Connis, Ph.D., Woodinville, Washington; Brian Ginsberg, M.D., Durham, North Carolina; Carmen R. Green, M.D., Ann Arbor, Michigan; Mark J. Lema, M.D., Ph.D., Buffalo, New York; David G. Nickinovich, Ph.D., Bellevue, Washington; and Linda Jo Rice, M.D., St. Petersburg, Florida.

Received from the American Society of Anesthesiologists, Park Ridge, Illinois. Submitted for publication October 20, 2011. Accepted for publication October 20, 2011. Supported by the American Society of Anesthesiologists and developed under the direction of the Committee on Standards and Practice Parameters, Jeffrey L. Apfelbaum, M.D. (Chair). Approved by the ASA House of Delegates on October 19, 2011. A complete list of references used to develop these updated Guidelines, arranged alphabetically by author, is available as Supplemental Digital Content 1, <http://links.lww.com/ALN/A780>.

Address correspondence to the American Society of Anesthesiologists: 520 North Northwest Highway, Park Ridge, Illinois 60068-2573. These Practice Guidelines, as well as all published ASA Practice Parameters, may be obtained at no cost through the Journal Web site, www.anesthesiology.org.

* American Society of Anesthesiologists Task Force on Acute Pain Management: Practice guidelines for acute pain management in the perioperative setting: An updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. ANESTHESIOLOGY 2004; 100:1573-81.

Copyright © 2012, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2012; 116:248-73.

- What other guideline statements are available on this topic?
 - These Practice Guidelines update the "Practice Guidelines for Acute Pain Management in the Perioperative Setting" adopted by the ASA in 2003 and published in 2004.*
- Why was this guideline developed?
 - In October 2010, the Committee on Standards and Practice Parameters elected to collect new evidence to determine whether recommendations in the existing Practice Guidelines were supported by current evidence.
- How does this statement differ from existing guidelines?
 - New evidence presented includes an updated evaluation of scientific literature and findings from surveys of experts and randomly selected ASA members. The new findings did not necessitate a change in recommendations.
- Why does this statement differ from existing guidelines?
 - The ASA guidelines differ from the existing guidelines because they provide new evidence obtained from recent scientific literature as well as findings from new surveys of expert consultants and randomly selected ASA members.

the current literature, expert and practitioner opinion, open forum commentary, and clinical feasibility data.

This document updates the "Practice Guidelines for Acute Pain Management in the Perioperative Setting: An Updated Report by the American Society of Anesthesiologists Task Force on Acute Pain Management," adopted by the ASA in 2003 and published in 2004.*

Methodology

A. Definition of Acute Pain Management in the Perioperative Setting

For these Guidelines, acute pain is defined as pain that is present in a surgical patient after a procedure. Such pain may be the result of trauma from the procedure or procedure-related complications. Pain management in the perioperative setting refers to actions before, during, and after a procedure

⊕ Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal's Web site (www.anesthesiology.org).

Project number: 585927-EPP-1-2017-1-

Preoperativni pristup:

- Nastavljanje preop. terapije
- Tretman za redukciju preop. bola
- Premedikacija i anksioliza
- Edukacija bolesnika i porodice


Perioperativni pristup:

- centralna neuroaxijalna analgezija
- PCA – intravenska/epiduralna
- periferna regionalna analgezija

ASA preporuke:

- opioidi i.v., PCA, neuroaxialno
- ne i.m. na zahtev bolesnika

Postoperative Pain Management – Good Clinical Practice



General recommendations
and principles for
successful pain management



Produced in consultation with the
European Society of Regional Anaesthesia
and Pain Therapy

Balansirana – multimodalna analgezija

A2-CBHE-JP (2017 – 3109 / 001 – 001)

"This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Multimodalne tehnike za postoperativnu analgeziju

Multimodalna tehnika:

korišćenje dva ili više analgetika sa različitim mehanizmom analgetskog dejstva.

- analgetici mogu biti primenjeni istim putem ili različitim

ASA preporuke:

- kad god je moguće koristiti multimodalnu tehniku
- razmotriti primenu centralnih neuroblokova/lokalni anestetici

+

NSAIDs, COXIBs ili acetaminofen

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

Analgetici

Pharmacological options of pain management

Non-opioid analgesics

Paracetamol
NSAIDs, including COX-2 inhibitors*
Gabapentin, pregabalin²

Weak opioids

Codeine
Tramadol
Paracetamol combined with codeine
or tramadol

Strong opioids

Morphine
Diamorphine
Pethidine
Piritramide
Oxycodone

Adjuvants**

Ketamine
Clonidine

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Multimodalne tehnike za postoperativnu analgeziju

Neuroaxialno: morfin + LA

sufentanil + LA

Sistemski: opioidi (Mo, fentanil, sufentanil, tramadol)

+

NSAIDs

COX NSAIDs

Pregabalin

Gabapentin

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Mild intensity pain

For example:

Inguinal hernia
Varices
Laparoscopy

Moderate intensity pain

For example:

Hip replacement
Hysterectomy
Jaw surgery

Severe intensity pain

For example:

Thoracotomy
Upper abdominal surgery
Aortic surgery
Knee replacement

- (i) Paracetamol and wound infiltration with local anaesthetic
- (ii) NSAIDs (unless contraindicated) and
- (iii) Epidural local analgesia or major peripheral nerve or plexus block or opioid injection (IV PCA)

- (i) Paracetamol and wound infiltration with local anaesthetic
- (ii) NSAIDs (unless contraindicated) and
- (iii) Peripheral nerve block (single shot or continuous infusion) or opioid injection (IV PCA)

- (i) Paracetamol and wound infiltration with local anaesthetic
- (ii) NSAIDs (unless contraindicated) and
- (iii) Regional block analgesia
Add weak opioid or rescue analgesia with small increments of intravenous strong opioid if necessary

CBHE-JP (2017 – 3109 / 001 – 001)

tion reflects the views only of the author, and the Commission cannot be held responsible for any information contained therein"

Morfijum

Morphine

Administration	(i) Intravenous. (ii) Subcutaneous by continuous infusion or intermittent boluses via indwelling cannula. (iii) Intramuscular (not recommended due to incidence of pain. 5-10 mg 3-4 hourly).
Dosage: IV PCA Subcutaneous	Bolus: 1-2 mg, lockout: 5-15 min (usually 7-8 min), no background infusion. 0.1-0.15 mg/kg 4-6 hourly, adapted in relation to pain score, sedation and respiratory rate.
Monitoring	Pain score, sedation, respiratory rate, side effects.
Comments	Side effects such as nausea, vomiting, sedation and apnoea. No other opioid or sedative drug should be administered.

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Tramadol

Tramadol

Administration

- (i) Intravenous: inject slowly (risk of high incidence of NV).
- (ii) Intramuscular.
- (iii) Oral administration as soon as possible.

Dosage

50-100 mg 6 hourly.

Monitoring

Pain score, sedation, respiratory rate, side effects.

Comments

Tramadol reduces serotonin and norepinephrine reuptake and is a weak opioid agonist.
In analgesic efficiency, 100 mg tramadol is equivalent to 5-15 mg morphine.
Sedative drugs can have an additive effect.

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Paracetamol

Paracetamol

Administration	(i) Intravenous: Start 30 min before the end of surgery. (ii) Oral administration as soon as possible. Duration: as long as required.
Dosage	4 x 1 g paracetamol/day (2 g propacetamol/day). Dose to be reduced (e.g. 3 x 1 g/day) in case of hepatic insufficiency.
Monitoring	Pain scores.
Comments	Should be combined with NSAID and/or opioids or loco-regional analgesia for moderate to severe pain.

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Nesteroidni antiinflamatori lekovi

NSAIDs¹

Administration

- (i) Intravenous: administration should start at least 30-60 min before end of surgery.
- (ii) Oral administration should start as soon as possible.
Duration: 3-5 days.

Dosage examples

(i) *Conventional NSAIDs include:*
ketorolac: 3 x 30-40 mg/day (only IV form)
diclofenac: 2 x 75 mg/day
ketoprofen: 4 x 50 mg/day
(ii) *Selective NSAIDs include:*
meloxicam 15 mg once daily
COX-2 inhibitors are now licensed for postoperative pain management. They are as efficient as ketorolac but reduce GI side effects. Examples include: parecoxib: 40 mg followed by 1-2 x 40 mg/day (IV form) or celecoxib: 200 mg/day. However, there is some debate due to cardiovascular risks in patients with arteriosclerosis. *See note below Table 2, page 17

Monitoring

Pain scores.
Renal function in patients with renal or cardiac disease, elderly patients, or patients with episodes of severe hypotension. Gastrointestinal side effects. Non-selective NSAIDs would be combined with proton inhibitors (i.e. omeprazol) in patients at risk of gastrointestinal side effects.

Comments

Can be added to the pre-medication.
Can be used in association with paracetamol and/or opioids or local regional analgesia for moderate to severe pain.

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

Analgetici

Analgetik	Način primene	Doza	Vremenski interval
Morfin	i.v.	1-2 mg	
Petidin (Meperidin)	i.v., i.m.	0.5-1.5 mg/kg	na 4-6 h
Tramadol	i.v., i.m., s.c.	50-100 mg	na 6 h
Paracetamol	i.v.	1 g	na 6 h
NSAIL-neselektivni COX inhibitori			
Ketorolak	i.v.	30-40 mg	na 6 h
Diklofenak	i.v.	75 mg	na 12 h
Ketoprofen	i.v.	50 mg	na 6 h
NSAIL-selektivni COX-2 inhibitori			
Celecoxib	Per os	200 mg	jednom dnevno
Meloxicam	Per os	15 mg	jednom dnevno
Parecoxib	i.v.	40 mg	1-2 puta dnevno

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

PCA – i.v.

Koncentracija leka	Bolus	Sigurnosni interval	Kontinuirana infuzija
Morfin (1 mg/ml)	0.5-2.5 mg	5-10 minuta	0.01-0.03 mg/kg/h
Fentanil (0.01 mg/ml)	10-20 µg	5-10 minuta	0.05-0.1 µg/kg/h

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

PCEA

Lek	Potrebna doza	Sigurnosni interval	Kontinuirana infuzija
Morfin	100–200 µg	10–15 minuta	300–600 µg/h
Fentanil	10–15 µg	6 minuta	80–120 µg/h
Bupivacain 0.125% + fentanil 4µg /ml	2 ml	10 minuta	4 ml/h
Ropivacain 0.2% + fentanil 5 µg /ml	2 ml	20 minuta	5 ml/h

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

Zaključak

Procena bola

Dokumentovanje

Multimodalna analgezija

Protokol za analgeziju

Izbor i dozu analgetika prilagoditi bolesniku, operativnom zahvatu, prisustvu drugih oboljenja ili bolnih sindroma

Project number: 585927-EPP-1-2017-1-RS-EPPKA2-CBHE-JP (2017 – 3109 / 001 – 001)

"This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein"

HVALA NA PAŽNJI

